ForteBio Launches Octet HTX System for Accelerated Drug Development

ForteBio, a division of Pall Life Sciences and a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch of the Octet® HTX system, the new flagship member of the Octet line of label-free interaction analysis systems. The Octet HTX system addresses the acute industry need for increased analysis speed and sample throughput when characterizing large numbers of therapeutic candidates.

Octet systems provide unique insights into drug-target binding interactions, insights that are used to fine-tune the affinity and specificity of drug molecules. The Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously, a capability offered by no other stand-alone label-free platform. The system offers dramatic time savings for researchers studying large panels of drug candidates, and provides innovative data analysis tools for developers of monoclonal antibodies and other biotherapeutic entities. In addition, the Octet HTX performs full 96-well plate determinations of protein concentrations in as little as 2 minutes.

“The need for higher analytical throughput is a central theme with our pharmaceutical and biopharm customers,” noted Robert Wicke, General Manager at Pall’s ForteBio Division. “We believe researchers will be delighted by the Octet HTX system. The HTX system was engineered for speed while maintaining peak performance, and will directly address critical bottlenecks in the drug development process.”

The Octet HTX system was unveiled at the BioProcess International 2013 conference in Boston, Mass.